tbuckley/cabot-search huggingface dataset:
Plasma Neutralization of the SARS-CoV-2 Omicron Variant
Authors: Fabian Schmidt, Frauke Muecksch, Yiska Weisblum, Justin Da Silva, Eva Bednarski, Alice Cho, Zijun Wang, Christian Gaebler, Marina Caskey, Michel C Nussenzweig, Theodora Hatziioannou, Paul D Bieniasz
Journal: New England Journal of Medicine (2021)

Plasma Neutralization of the SARS-CoV-2 Omicron VariantTo The Editor: The newly emerged B.1.1.159(omicron) variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) 1 has a large number of changes -32 -in its spike protein relative to that of the original virus (Wuhan-hu-1), particularly in the receptor-binding domain and the N-terminal domain, the primary targets of neutralizing antibodies.Previously, we showed that approximately 20 changes introduced into a synthetic polymutant spike protein (PMS20) are sufficient for substantial evasion of the polyclonal neutralizing antibodies elicited in the majority of persons who have recovered from coronavirus disease 2019 (Covid-19) or have received two doses of an mRNA vaccine. 2 Of note, several changes in the PMS20 spike protein are the same as or similar to changes in the omicron variant (Fig. S1 in the Supplementary Appendix, available with the full text of this letter at NEJM.org).4][5] In plasma specimens obtained at approximately 1 month and 6 months after infection from persons who had recovered from Covid-19, the 50% neutralization titer (NT 50 ) values were a mean (±SD) of 60±47 and 37±27 times lower for PMS20 than for Wuhan-hu-1, respectively, and 58±51 and 32±23 times lower for omicron than for Wuhan-hu-1 (Fig. S2A andS2B).Similarly, plasma specimens obtained from different persons in the same cohort 1 year after infection had NT 50 values that were 34±24 times lower for PMS20 and 43±23 times lower for omicron than for Wuhan-hu-1 (Fig. S2C).
Lectures ON DISEASES OF THE MALE URETHRA
Authors: F. S. Kidd
Journal: BMJ (1917)

The splint shouild then be removed, the hand should be heated, and active-anid-passive movetmleilts of tlle joints carried out.The actual gain fronm day to day may be very small, but excellent results can generally be achiieved if thie treatment is persisted in.For tlle treatment of contracted conditions of the flexors of the forearmn several methods of applying continuous traction are available.Spl)ints with springs or elastic accumulators applied to the posterior aspect of the limb are, on the whole, rather unsatisfactory.The plan of tying weights to the forearmn mjay be of some effect, but it does not commend itself to the patient.TThe best results are obtained by placing the patient on hie back on an ordinary muassage t oucl.His shoulder and -clest are fixed to tihe couclh by adjiustable strappings.A-firm pad-is pladed tinder the flexed elbow, and traction is.applied in the line of the armi by attaclhing a strong cord to the wrist, passing it over a pulley at the bottom of the couch, and fasteniing it below.After five or ten minutes the cord becomes noticeably slack as tlle flexion yields, aind it r-equires to be tighltenied up at intervals.Cases steadily-iwptove if tlis-treatibeit is 6arried out tor periods of an hour twice a day.The pectoral mtuscles cani bd stretchled in simlilar faslhion by tyijng the exteiided arm- back to some object in the room, the weialgt of the limib being sustained by a small table placed under thie forearm.TThe Zander nystemprovides an excellent imietlhod for the exercise of both passive and active movements.The macllines can be adjusted, either passively to stretch con- tracted tissues or to provi(le a resistance against which the muscles are encouraged to contract.The action is a rhytlhmical one, and its value lies in the fact tlhat the force is evenly exerted without sudden jar or strain; tlhin is.effected by :an adjustable syst4m of counterpoise, the action of which resembles in ome measure thie steadying and controlling effect-exercise'I by antagonistic.muwles drring the eositrvation of their opponents.-The Zander pInehia6s aee expesiaive;-but where iarge -umbers of.-esesare tieatedtey very soon repay their cost.Whatever line of treatment.is.oopted-restoration of function, and voluntary exercise of the affected -iulb slhould bb encouraged from the earliest possible momenit; and interference with the function of the muscies con- cerned should be as limited as is-consistent with the treatment being carred out.1 am obliged-to Colonel T. Lucas, C.B., for his kind permission to publislh this paper.
Fellowships, Grants, Awards
Journal: JNCI Journal of the National Cancer Institute (1992)

Fellowships, Grants, Awards JNCI: Journal of the National Cancer Institute, Volume 84, Issue 21, 4 November 1992, Pages 1677–1678, https://doi.org/10.1093/jnci/84.21.1677 Published: 04 November 1992
Pasteurella multocida
Authors: Donald P. Francis
Journal: JAMA (1975)

<i>Pasteurella multocida</i>is a common cause of infection following bites or scratches caused by dogs and cats. However, it is rarely reported and apparently often overlooked as a pathogen. It causes the typical clinical manifestations of a rapidly developing cellulitis at the site of injury. The infection is potentially dangerous and can cause a chronic local infection of deep tissues and septicemia. However, it responds well to several antimicrobials, with penicillin being the drug of choice. (<i>JAMA</i>233:42-45, 1975)
Enoxaparin versus tinzaparin in the management of unstable coronary artery disease (EVET study) Lambros K. Michalis, Nicolaos Papamichail, Christos S. Katsouras, Ageliki Karahaliou, Eleni Sourla, John Novas, Lambros Sioros, Andreas Papalambrakopoulos, John A. Goudevenos, Dimitris A. Sideris. University Hospital of Ioannina, Ioannina, Greece
Journal: Journal of the American College of Cardiology (2001)
T cells: Friends and foes in NASH pathogenesis and hepatocarcinogenesis
Authors: Pierluigi Ramadori, Shing Kam, Mathias Heikenwalder
Journal: Hepatology (2022)

Abstract In association with the pandemic spreading of obesity and metabolic syndrome, the prevalence of NAFLD‐related HCC is increasing almost exponentially. In recent years, many of the underlining multifactorial causes of NAFLD have been identified, and the cellular mechanisms sustaining disease development have been dissected up to the single‐cell level. However, there is still an urgent need to provide clinicians with more therapeutic targets, with particular attention on NAFLD‐induced HCC, where immune checkpoint inhibitors do not work as efficiently. Whereas much effort has been invested in elucidating the role of innate immune response in the hepatic NAFLD microenvironment, only in the past decade have novel critical roles been unraveled for T cells in driving chronic inflammation toward HCC. The metabolic and immune microenvironment interact to recreate a tumor‐promoting and immune‐suppressive terrain, responsible for resistance to anticancer therapy. In this article, we will review the specific functions of several T‐cell populations involved in NAFLD and NAFLD‐driven HCC. We will illustrate the cellular crosstalk with other immune cells, regulatory networks or stimulatory effects of these interactions, and role of the metabolic microenvironment in influencing immune cell functionality. Finally, we will present the pros and cons of the current therapeutic strategies against NAFLD‐related HCC and delineate possible novel approaches for the future.
Matt Morgan: Your 1800 weeks of work
Authors: Matt Morgan
Journal: BMJ (2022)

As another year ticks silently into the next, along with the resolutions broken, I reflect on my place as a speck on this Earth.My Christmas gift of a brilliant book by Oliver Burkeman, Four Thousand Weeks: Time Management for Mortals, 1 has helped to make this seemingly morbid festive activity feel life affirming.With just 4000 weeks or so in an average human life, Burkeman-a self-confessed recovering productivity geek-argues that we concentrate too much on getting more and more done while forgetting what it is in life that really matters.In any life there will always be too much to do, and, with the whole of documented human civilisation contained within the span of just 60 centenarian lifetimes in a row, you are really no big deal.Instead of denting the universe, Burkeman argues, what really matters is "making some tiny contribution to the betterment of the environment, or your neighborhood, or the political culture."It struck me that those 4000 weeks of my life will contain 1800 weeks of caring for patients.Eighteen hundred weeks of work.Boiling your entire career down to these simple numbers may help you to move from last year to the next with a different view of how you relate to time, to people, and to yourself.In any career in healthcare there will always be too much to do.As the whole of medicine's documented history could be contained within the span of just 20 centenarian human lifetimes, you can make a big difference.Not in an Elon Musk, dent-the-universe kind of way, but by making tiny improvements for patients, for your colleagues, or to the health systems people rely on.These seemingly insignificant gestures are not only enough-they are the ones that really matter.And, while the 24 hour news channels batter us with gloom, not everything that weighs us down is ours to carry.Allow the good days to bring you happiness; the bad ones will bring experience of this short life and even shorter career.So, when making resolutions for the next 52 weeks of your life in medicine, remember that the true value of any time management strategy lies in it helping you to neglect the things that don't really matter.
<i>Erratum:</i> Vol. 69, No. 49
Journal: MMWR Morbidity and Mortality Weekly Report (2021)

on page 1842, the fourth sentence in the third complete paragraph should have read "The change in mean ED visits related to child abuse and neglect per week during the early pandemic period (March 29-April 25, 2020) and the comparison period (March 31-April 27, 2019) was calculated as the mean difference in total ED visits related to child abuse and neglect between the two 4-week periods."
Risk of Foot Ulcer and Lower-Extremity Amputation Among Participants in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study
Authors: Edward J. Boyko, Leila R. Zelnick, Barbara H. Braffett, Rodica Pop-Busui, Catherine C. Cowie, Gayle M. Lorenzi, Rose Gubitosi-Klug, Bernard Zinman, Ian H. de Boer
Journal: Diabetes Care (2022)

Intensive glycemic control reduces the risk of kidney, retinal, and neurologic complications in type 1 diabetes (T1D), but whether it reduces the risk of lower-extremity complications is unknown. We examined whether former intensive versus conventional glycemic control among Diabetes Control and Complications Trial (DCCT) participants with T1D reduced the long-term risk of diabetic foot ulcers (DFUs) and lower-extremity amputations (LEAs) in the subsequent Epidemiology of Diabetes Interventions and Complications (EDIC) study.DCCT participants (n = 1,441) completed 6.5 years on average of intensive versus conventional diabetes treatment, after which 1,408 were enrolled in EDIC and followed annually over 23 years for DFU and LEA occurrences by physical examination. Multivariable Cox proportional hazard regression models estimated associations of DCCT treatment assignment and time-updated exposures with DFU or LEA.Intensive versus conventional glycemic control was associated with a significant risk reduction for all DFUs (hazard ratio 0.77 [95% CI 0.60, 0.97]) and a similar magnitude but nonsignificant risk reduction for first-recorded DFUs (0.78 [0.59, 1.03]) and first LEAs (0.70 [0.36, 1.36]). In adjusted Cox models, clinical neuropathy, lower sural nerve conduction velocity, and cardiovascular autonomic neuropathy were associated with higher DFU risk; estimated glomerular filtration rate <60 mL/min/1.73 m2, albuminuria, and macular edema with higher LEA risk; and any retinopathy and greater time-weighted mean DCCT/EDIC HbA1c with higher risk of both outcomes (P < 0.05).Early intensive glycemic control decreases long-term DFU risk, the most important antecedent in the causal pathway to LEA.
The need for reporting guidelines for early phase dose-finding trials: Dose-Finding CONSORT Extension
Authors: Christina Yap, Alun Bedding, Johann de Bono, Munyaradzi Dimairo, Aude Espinasse, Jeffry Evans, Sally Hopewell, Thomas Jaki, Andrew Kightley, Shing Lee, Rong Liu, Adrian Mander, Olga Solovyeva, Christopher J. Weir
Journal: Nature Medicine (2022)
Retrospective analysis of arterial occlusive events in the PACE trial by an independent adjudication committee
Authors: James L. Januzzi, Joseph M. Garasic, Scott E. Kasner, Vickie McDonald, Mark C. Petrie, Jonathan Seltzer, Michael Mauro, Kevin Croce, Ellin Berman, Michael Deininger, Andreas Hochhaus, Javier Pinilla-Ibarz, Franck Nicolini, Dong-Wook Kim, Daniel J. DeAngelo, Hagop Kantarjian, Jing Xu, Tracey Hall, Shouryadeep Srivastava, Daniel Naranjo, Jorge Cortes
Journal: Journal of Hematology & Oncology (2022)

Abstract Background The phase 2 PACE (Ponatinib Ph+ ALL and CML Evaluation) trial of ponatinib showed robust long-term benefit in relapsed Philadelphia chromosome-positive (Ph+) leukemia; arterial occlusive events (AOEs) occurred in ≥ 25% of patients based on investigator reporting. However, AOE rates vary depending on the definitions and reporting approach used. Methods To better understand clinically relevant AOEs with ponatinib, an independent cardiovascular adjudication committee reviewed 5-year AOE data from the PACE trial according to a charter-defined process and standardized event definitions. Results A total of 449 patients with chronic myeloid leukemia (CML) or Ph+ acute lymphoblastic leukemia (ALL) received ponatinib (median age 59 y; 47% female; 93% ≥ 2 prior tyrosine kinase inhibitors (TKIs); median follow-up, 37.3 months). The adjudicated AOE rate (17%) was lower than the non-adjudicated rate (i.e., rate before adjudication; 25%). The only adjudicated AOE in &gt; 2% of patients was peripheral arterial occlusive disease (4%). Exposure-adjusted incidence of newly occurring adjudicated AOEs decreased over time. Patients with multiple baseline cardiovascular risk factors had higher adjudicated AOE rates than those without risk factors. Conclusions This independent adjudication study identified lower AOE rates than previously reported, suggesting earlier overestimation that may inaccurately reflect AOE risk with ponatinib. This trial was registered under ClinicalTrials.gov identifier NCT01207440 on September 23, 2010 ( https://clinicaltrials.gov/ct2/show/NCT01207440 ).
Research brief
Authors: Jane Bradbury
Journal: The Lancet Infectious Diseases (2014)

Results of a phase 1 study in 12 aviraemic HIV-positive patients receiving antiretroviral therapy (ART) suggest that it might be possible to use gene editing to induce genetic resistance to HIV infection. Researchers used a targeted zinc-finger nuclease to inactivate the chemokine (C-C motif) receptor 5 gene (CCR5), which encodes a coreceptor for HIV entry, in autologous CD4 T cells. The modified cells persisted well after adoptive transfer into the patients. In six patients in whom ART was interrupted, the decline of modified cells was less than that of unmodified cells during the resultant viraemia.
ST segment slope alone detects exercise-induced myocardial ischemia in body surface potential mapping Helena Hanninen, Panu Takala, Petri Korhonen, Lasse Oikarinen, Juha Montonen, Markku Makijarvi, Jukka Nenonen, Kim Simelius, Toivo Katila, Lauri Toivonen. Helsinki University Central Hospital, Helsinki, Finland, Helsinki University of Technology, Espoo, Finland
Journal: Journal of the American College of Cardiology (2001)
Orthopedic Surgery.
Journal: JAMA (1923)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
68Ga-DOTATATE Uptake in an Intraosseous Hemangioma, as a Potential Cause of False-Positive PET/CT Finding, Simulating Tumoral Involvement
Authors: Bahare Saidi, Babak Fallahi, Reyhaneh Manafi-Farid, Armaghan Fard-Esfahani, Mohammad Eftekhari
Journal: Clinical Nuclear Medicine (2022)

We present the case of a 32-year-old man with a history of hypophosphatemia and multiple bone fractures, being evaluated at our center for a potential mesenchymal tumor. 68Ga-DOTATATE PET/CT revealed a highly 68Ga-DOTATATE-avid lesion in the ethmoidal sinus extending to the nasal cavity. Following resection, histologic examination of the specimen confirmed the diagnosis of "intraosseous hemangioma," a potential cause of false-positive finding of 68Ga-DOTATATE PET/CT imaging in patients being evaluated for occult malignancies, especially at the traumatic/fractured sites.
Viral hepatitis.
Authors: J Y Lau, G J Alexander, A Alberti
Journal: Gut (1991)

Viral hepatitis continues to be a major global health problem.It is therefore, not surprising that viral hepatitis has been one of the research domains in the Institute of Liver Studies in King's.With the advancement ofmany scientific disciplines including molecular biology and immunology, we have witnessed an explosion in knowledge of these viruses in the last two decades.We now know that there are at least five major types of primary hepatotrophic hepatitis viruses (Table I).Acute hepatitis caused by other viruses in whom involvement of other organs are more common and prominent than liver involvement notably cytomegalovirus and herpes simplex virus is not described here.HAV detected in stool.
Attending Rounds
Authors: George A Sarosi
Journal: Annals of Internal Medicine (2010)

On Being a Doctor5 October 2010Attending RoundsGeorge A. Sarosi, MDGeorge A. Sarosi, MDFrom University of Minnesota, Minneapolis, MN 55417.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-153-7-201010050-00016 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail It is done! Finally, all the notes are written, all the discharge summaries are signed, and I lean back to do a little reflecting on the day's events and how it was before: It is October 1963, somewhere in the Northeast United States. I am the senior medical student sharing the on-call room with the intern. The telephone is next to me. The hospital operator rings. “Doctor, you wanted a wake-up call for 5:45.”Time to roll out of bed and start drawing blood and doing CBCs on all of our patients. By 7:00 a.m., we've completed this. We have ... Author, Article, and Disclosure InformationAffiliations: From University of Minnesota, Minneapolis, MN 55417.Corresponding Author: George A. Sarosi, MD, University of Minnesota, Minneapolis Veterans Affairs Medical Center, One Veterans Drive, Minneapolis, MN 55417; e-mail, george.[email protected]gov. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byIs Nephrology Fellowship Training on the Right Track? 5 October 2010Volume 153, Issue 7Page: 482KeywordsBloodChartsNursesPenicillinPneumoniaResearch laboratoriesSputumSystematic reviewsThoraxUrine ePublished: 5 October 2010 Issue Published: 5 October 2010 Copyright & PermissionsCopyright © 2010 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
International Abstracts
Journal: JAMA (1987)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
The effect of glycoprotein (GP) IIb/IIIa receptor inhibitor, tirofiban, on the microcirculation in patients undergoing high-risk coronary stenting Philip Wong, Joseph K. Choo, Ignacio Inglessis, C Joon Choi, Stephen N. Oesterle, Giorgio Gimelli, Ik-Kyung Jang. Massachusetts General Hospital, Boston, MA
Journal: Journal of the American College of Cardiology (2001)
Post-COVID-19 spending
Authors: None The Lancet Planetary Health
Journal: The Lancet Planetary Health (2020)

The majority of countries have instigated some form of lockdown in order to slow the spread of SARS-CoV-2. Governments seem rather reluctant to discuss what will come next. Presumably this is because they are prioritising clarity of message over information dissemination. Clearly there is a balance to be struck between the provision of accurate and concise information about the current situation and the more speculative scenario exercises needed to plan for an exit strategy. Nevertheless, how long lockdowns continue and how governments go about helping the economy to recover matters a great deal and so inevitably there is much speculation anyway.
Persistent ductal constriction during uterine life and left ventricular remodeling in neonatal rats by maternally administered indomethacin Manatomo Toyono, Kenji Harada, Tomomi Orino, Masamichi Tamura, Kenji Yasuoka, Goro Takada. Akita University, Akita, Japan
Journal: Journal of the American College of Cardiology (2001)
Poliomyelitis: the battle continues
Authors: S. K. Yarnell
Journal: JAMA (1989)

In 1979, Larry Schneider, a poliomyelitis survivor from Tucson, Ariz, wrote a letter to the editor of the<i>Rehabilitation Gazette</i>regarding the recent onset of pain, inexplicable fatigue, and a sense of progressing weakness 30 years after the onset of polio.<sup>1</sup>He asked whether other polio survivors had noticed comparable symptoms. The subsequent flood of correspondence to editor Gini Lauri so astounded her that she called together a network of medical specialists and polio survivors for the First International Post-Polio Symposium in Chicago, Ill, in 1981. The ensuing presentations and discussions defined the scope of the problem of postpolio sequelae. Most in attendance agreed that postpolio-related problems were not truly a syndrome in the classic sense, because not all polio survivors develop all the same symptoms. Commonly described symptoms include joint and muscular pain, unaccustomed fatigue or decreased stamina in daily activities, cold intolerance, worsening respiratory problems, and, most